Bamboocloud has garnered 300 million yuan ($44 million) in a Series C round of financing from Sequoia Capital China and Kunlun Fund, while ImmuneOnco Biopharma has secured $25 million in a Series B round led by Lilly Asia Ventures.
Bamboocloud bags $44m Series C round
Chinese identity and access management (IAM) platform Bamboocloud has garnered 300 million yuan ($44 million) in a Series C round of financing from Sequoia Capital China and Kunlun Fund, a Beijing-based private equity firm focused on TMT (technology, media, telecom) and new consumption, Bamboocloud posted on WeChat on Monday.
